The Race for Alzheimer’s Treatment: EU Rejects Eli Lilly’s Drug Over Safety Concerns

The European Medicines Agency (EMA) has turned down Eli Lilly’s experimental Alzheimer’s treatment, Kisunla (donanemab), after determining that its modest benefits in slowing cognitive decline do not justify the risk of serious brain swelling.

In its decision, the EMA cited that while the drug offers a slight deceleration in cognitive deterioration, the potential for dangerous side effects, including severe cerebral edema, poses an unacceptable risk to patients. This move places the spotlight on the safety profiles of emerging Alzheimer’s therapies amid a race to address a disease that affects millions across Europe.

The rejection also bolsters the position of rival treatments, notably Eisai and Biogen’s Leqembi (lecanemab), which has already received conditional backing from the agency for use in certain patient groups. The EMA had initially raised concerns over Leqembi’s safety, but subsequent adjustments and targeted recommendations allowed it to gain favor as a potentially viable option for patients with a lower genetic predisposition to adverse effects.

Eli Lilly, however, is not conceding defeat. The company has announced plans to appeal the ruling, with executive vice president Ilya Yuffa expressing optimism that further dialogue with the EMA might eventually pave the way for Kisunla’s approval. “We remain committed to advancing treatments for Alzheimer’s and will continue our efforts to ensure patient safety while delivering therapeutic benefits,” Yuffa stated.

This decision comes at a time when the European healthcare community is under pressure to find effective treatments for Alzheimer’s disease, which currently affects an estimated 7 million people on the continent. As regulatory bodies weigh innovation against patient safety, the EMA’s cautious stance underscores the complex challenges of approving new therapies for a condition that continues to demand urgent medical breakthroughs.

The appeal process is expected to unfold over the coming months, with industry experts closely watching whether additional data or revised protocols might sway regulators in favor of Kisunla.